P
Pyxis Oncology
Pyxis Oncology antibody therapeutics | Cancer immunotherapy | Boston
About Pyxis Oncology
Pyxis Oncology is a biotechnology company focused on developing advanced cancer treatments through innovative antibody-drug conjugates (ADCs) and immuno-oncology (IO) therapies. The company aims to deliver potent cancer-killing agents directly to tumor cells, enhancing efficacy while minimizing toxicity. Pyxis Oncology serves patients with various types of cancer, operating in the highly competitive oncology market. Its business model revolves around leveraging its proprietary technology platforms to create safer and more effective ADCs and IO therapies. Revenue is generated through partnerships, licensing agreements, and potentially future product sales. The company is led by seasoned life sciences executive John Flavin, who has extensive experience in finance, operations, and innovation within the life sciences sector.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Boston, United States
- Employees
- 68
- Open positions
- None listed
- Dealroom signal
- 83.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest May 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Jun 2026 | $114M | — | BVF Partners · RTW Investments · Coastlands Capital · GordonMD Global Investment | ↗ |
| PRIVATE PLACEMENT VCOther financing | Feb 2024 | $50M | — | Deep Track Capital · Blue Owl Capital · Ridgeback Capital · Laurion Capital Management | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Pyxis Oncology is 5.5K monthly website visits, down 16.7% over the last three months. Pyxis Oncology's team declined 1.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A19 investors entered at this stage
Leaps by Bayer
Longwood Fund
Agent Capital
Ipsen
Arix Bioscience
RTW Investments
Citadel
RA Capital Management- PVPfizer Ventures
Logos Capital
Laurion Capital Management- TMTekla Capital Management
BVF Partners
Cormorant Asset Management
Janus Henderson Investors
Perceptive Advisors
LifeSci Venture Partners
Ridgeback Capital- APAcuta Capital Partners
Other known investors6 additional known investors
Blue Owl Capital- CCCoastlands Capital
Deep Track Capital
GordonMD Global Investment
Polsky Center
StemPoint Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pyxis Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pyxis Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.